Premature baby – European Clinical Trials Information Network

Study on the Effect of Caffeine Citrate for Patients with Extubation Failure and Bronchopulmonary Dysplasia

Wed, 29 Apr 2026 15:03:19 +0000

This clinical trial is focused on studying the effects of an additional dose of caffeine citrate in preterm newborns who are at risk of extubation failure and bronchopulmonary dysplasia. Extubation failure occurs when a baby has difficulty breathing on their own after being taken off a breathing machine, while bronchopulmonary dysplasia is a lung condition that can affect premature infants. The treatment being tested is a solution of caffeine citrate, which is given through an injection to help stimulate breathing.

The purpose of the study is to see if giving an extra dose of caffeine citrate before removing the breathing tube can improve the chances of successful extubation. The study will monitor the need for reintubation, which means putting the breathing tube back in if the baby struggles to breathe on their own. It will also look at other factors like the frequency of breathing pauses (apneas), side effects such as increased heart rate or blood pressure, and any digestive issues. Additionally, the study will observe the development of conditions like necrotizing enterocolitis, a serious intestinal disease, and the progression of brain-related issues such as intraventricular hemorrhage or periventricular leukomalacia.

The trial will follow the participants over a period to assess their neurodevelopmental outcome, which refers to how well their brain develops and functions over time. The study aims to provide valuable insights into whether this additional caffeine citrate dose can help improve breathing outcomes and overall health in these vulnerable infants.

Study on Budesonide and Poractant Alfa for Preventing Lung Disease in Very Preterm Infants

Wed, 29 Apr 2026 15:02:54 +0000

This clinical trial is focused on studying a condition called Bronchopulmonary Dysplasia (BPD), which affects the lungs of very preterm infants, specifically those born at or before 32 weeks of gestation. The study aims to explore the effectiveness and safety of a treatment that combines two medications: Budesonide and a surfactant called Poractant Alfa. Budesonide is a type of medication known as a corticosteroid, which helps reduce inflammation, while Poractant Alfa is a surfactant that helps the lungs function better by reducing surface tension in the airways.

The purpose of the study is to see if the combination of Budesonide and Poractant Alfa can help prevent BPD in these very preterm infants. During the study, some infants will receive the combination treatment, while others will receive only the surfactant. The study will monitor the infants’ lung health and inflammation levels over time, using methods like lung ultrasound and checking for specific markers in their respiratory system. The safety of the treatment will also be closely observed, looking for any potential side effects or complications.

The study will follow the infants for a period of time to assess their lung development and overall health. This includes checking their need for oxygen and respiratory support, as well as evaluating their neurodevelopment at two years of age. The goal is to gather information that could lead to better treatments for preventing BPD in preterm infants, ultimately improving their long-term health outcomes.

Study on the Effects of 30% vs. 60% Oxygen Levels at Birth for Improving Development in Premature Infants

Wed, 29 Apr 2026 14:29:44 +0000

This clinical trial is focused on studying the effects of different oxygen levels on the development of very low birthweight infants who are born prematurely. Premature birth, or prematurity, occurs when a baby is born before 37 weeks of pregnancy. The study will use Medical Oxygen, which is a type of oxygen used in medical settings, to see if starting with a higher concentration of 60% oxygen compared to a lower concentration of 30% oxygen at birth can improve the infants’ development by the time they reach 18 to 24 months of age.

The purpose of the study is to determine if there is any difference in the rate of survival or developmental outcomes between the two oxygen levels. The study will follow the infants from birth until they are 18 to 24 months old. During this time, researchers will monitor the infants for any major developmental issues, such as difficulties with movement, severe learning delays, hearing problems that require aids, or significant vision problems.

In addition to the main outcomes, the study will also look at other health issues that might occur in the hospital, such as severe brain injuries, a lung condition called bronchopulmonary dysplasia, and a serious eye condition known as retinopathy of prematurity. The study aims to provide valuable information on how different oxygen levels at birth can affect the health and development of premature infants.